Pharmacological Interventions for the Prevention of Antipsychotic-Induced Weight Gain in People With Schizophrenia: A Cochrane Systematic Review and Meta-Analysis.
Sri Mahavir AgarwalNicolette StogiosGuy E J FaulknerMargaret K HahnPublished in: Schizophrenia bulletin (2023)
Patients with schizophrenia are burdened by higher rates of obesity, cardiovascular disease and reduced life expectancy than the general population. In addition to illness, genetic and lifestyle factors, the associated weight gain and metabolic adverse effects of antipsychotic (AP) medications are known to exacerbate and accelerate these cardiometabolic problems significantly. Given the detrimental consequences of weight gain and other metabolic disturbances, there is an urgent need for safe and effective strategies to manage these issues as early on as possible. This review summarizes the literature of adjunctive pharmacological interventions aimed at preventing AP-induced weight gain.
Keyphrases
- weight gain
- body mass index
- birth weight
- cardiovascular disease
- weight loss
- physical activity
- high glucose
- diabetic rats
- transcription factor
- type diabetes
- metabolic syndrome
- drug induced
- mental health
- systematic review
- gene expression
- oxidative stress
- genome wide
- endothelial cells
- emergency department
- dna methylation
- coronary artery disease
- skeletal muscle
- cardiovascular events